Eli Lilly partners with Area Health Systems on important antibody infusion therapies for COVID-19
Topics: ELI LILLY AREA HEALTH SYSTEMS
Multiple neutralizing antibody therapies, administered via intravenous infusion, have been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients.
The opening of these infusion centers provides additional dedicated locations in which people can receive COVID-19 infusion treatments.
Last week Ascension St. Vincent Evansville opened a dedicated infusion center to serve Hoosiers in southern Indiana who are high-risk COVID-19 patients.
Lilly has also partnered with the State of Indiana, Community Health Network, Eskenazi Health, and Franciscan Health on an infusion center serving the Central Indiana area and with Saint Joseph Health System, Beacon Health System, and Goshen Health System on an infusion center serving Northern Indiana.
These infusion centers have helped deliver antibody therapy to more than 1,700 Hoosiers with COVID-19 who are high risk. ■